Bristol-Myers Squibb Co
XBER:BRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
XBER:BRM
|
US |
|
C
|
Canadian Imperial Bank of Commerce
XBER:CAI
|
CA |
|
R
|
Restaurant Brands International Inc
LSE:0VFA
|
CA |
Bankruptcy Probability
Bristol-Myers Squibb Co's probability of bankruptcy is 1.9%, pointing to a small but noticeable default risk. The solvency score is 41/100 — a warning sign of potential financial weakness.
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Bristol-Myers Squibb Co Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
113.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
589.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
429.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
310.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
240.4B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
153.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
56.7B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Bristol-Myers Squibb Co's probability of bankruptcy is 1.9%, pointing to a small but noticeable default risk.
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Bristol-Myers Squibb Co has total debt of 42.5B USD. This includes both short-term (319m USD) and long-term (42.2B USD) debt.
You can find a full breakdown on its Balance Sheet.
